Text Size

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (ONTAK)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tyler Curiel, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00880360
First received: April 10, 2009
Last updated: January 7, 2013
Last verified: January 2013
History of Changes
Results First Received: August 13, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Epithelial Ovarian Cancer
Extraovarian Peritoneal Cancer
Fallopian Tube Carcinoma
Intervention: Drug: Ontak

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ontak Ontak : Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Participant Flow:   Overall Study
    Ontak  
STARTED     19  
COMPLETED     19  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Ontak Ontak : Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Baseline Measures
    Ontak  
Number of Participants  
[units: participants]
 		  19  
Age  
[units: participants]
 		 
<=18 years     0  
Between 18 and 65 years     11  
>=65 years     8  
Age  
[units: years]
Mean ± Standard Deviation 		  63  ± 1  
Gender  
[units: participants]
 		 
Female     19  
Male     0  
Region of Enrollment  
[units: participants]
 		 
United States     19  



  Outcome Measures

1.  Primary:   Number of Participants Demonstrating Clinical Response   [ Time Frame: 2 years ]
  Show Outcome Measure 1

2.  Secondary:   Toxicity   [ Time Frame: 3 years ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Dr. Tyler Curiel
Organization: University of Texas Health Science Center at San Antonio
phone: 210-450-1000
e-mail: curielt@uthscsa.edu


No publications provided


Responsible Party: Tyler Curiel, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT00880360     History of Changes
Obsolete Identifiers: NCT00238186
Other Study ID Numbers: HSC20070042H, OCR 07-04
Study First Received: April 10, 2009
Results First Received: August 13, 2012
Last Updated: January 7, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board